CAS 1155419-89-8 BI 224436

BI 224436 - CAS 1155419-89-8

Catalog number: 1155419-89-8

Not Intended for Therapeutic Use. For research use only.

Molecular Formula:
Molecular Formula	C27H26N2O4
Molecular Weight:
Molecular Weight	442.51
COA:
COA	Inquire
Targets:
Targets	HIV
Description:
Description	BI 224436 is a novel HIV-1 non-catalytic-site integrase inhibitor; has antiviral EC50s of <15 nM against different HIV-1 laboratory strains and cellular cytotoxicity of >90 μM.

Publication citing BOC Sciences Products

1. Tabanone, a new phytotoxic constituent of cogongrass (Imperata cylindrica)

2. A comparative assessment of human exposure to tetrabromobisphenol A and eight bisphenols including bisphenol A via indoor dust ingestion in twelve countries

3. Plasticizer composition which contains furan derivatives and terephthalic acid dialkyl esters

4. Depressed perivascular sensory innervation of mouse mesenteric arteries with advanced age

5. High-quality Italian rice cultivars: Chemical indices of ageing and aroma quality

6. Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism

>> More

Purity:
Purity	>98%
MSDS:
MSDS	Inquire

InChIKey:
InChIKey	MIXIIJCBELCMCZ-VWLOTQADSA-N
InChI:
InChI	InChI=1S/C27H26N2O4/c1-15-21(25(26(30)31)33-27(2,3)4)23(17-7-5-6-8-19(17)29-15)18-9-10-20-22-16(12-14-32-20)11-13-28-24(18)22/h5-11,13,25H,12,14H2,1-4H3,(H,30,31)/t25-/m0/s1
Canonical SMILES:
Canonical SMILES	CC1=NC2=CC=CC=C2C(=C1C(C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4

1.Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Fader LD1, Malenfant E1, Parisien M1, Carson R1, Bilodeau F1, Landry S1, Pesant M1, Brochu C1, Morin S1, Chabot C1, Halmos T1, Bousquet Y1, Bailey MD1, Kawai SH1, Coulombe R1, LaPlante S1, Jakalian A1, Bhardwaj PK1, Wernic D1, Schroeder P1, Amad M1, Edwar ACS Med Chem Lett. 2014 Jan 22;5(4):422-7. doi: 10.1021/ml500002n. eCollection 2014.

An assay recapitulating the 3' processing activity of HIV-1 integrase (IN) was used to screen the Boehringer Ingelheim compound collection. Hit-to-lead and lead optimization beginning with compound 1 established the importance of the C3 and C4 substituent to antiviral potency against viruses with different aa124/aa125 variants of IN. The importance of the C7 position on the serum shifted potency was established. Introduction of a quinoline substituent at the C4 position provided a balance of potency and metabolic stability. Combination of these findings ultimately led to the discovery of compound 26 (BI 224436), the first NCINI to advance into a phase Ia clinical trial.

2.Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor.

Fenwick C1, Amad M2, Bailey MD2, Bethell R2, Bös M2, Bonneau P2, Cordingley M2, Coulombe R2, Duan J2, Edwards P2, Fader LD1, Faucher AM2, Garneau M2, Jakalian A2, Kawai S2, Lamorte L2, LaPlante S2, Luo L2, Mason S2, Poupart MA2, Rioux N2, Schroeder P2, Si Antimicrob Agents Chemother. 2014 Jun;58(6):3233-44. doi: 10.1128/AAC.02719-13. Epub 2014 Mar 24.

BI 224436 is an HIV-1 integrase inhibitor with effective antiviral activity that acts through a mechanism that is distinct from that of integrase strand transfer inhibitors (INSTIs). This 3-quinolineacetic acid derivative series was identified using an enzymatic integrase long terminal repeat (LTR) DNA 3'-processing assay. A combination of medicinal chemistry, parallel synthesis, and structure-guided drug design led to the identification of BI 224436 as a candidate for preclinical profiling. It has antiviral 50% effective concentrations (EC50s) of <15 nM against different HIV-1 laboratory strains and cellular cytotoxicity of >90 μM. BI 224436 also has a low, ∼2.1-fold decrease in antiviral potency in the presence of 50% human serum and, by virtue of a steep dose-response curve slope, exhibits serum-shifted EC95 values ranging between 22 and 75 nM. Passage of virus in the presence of inhibitor selected for either A128T, A128N, or L102F primary resistance substitutions, all mapping to a conserved allosteric pocket on the catalytic core of integrase.

Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HIV Products

Peptide T
(CAS: 106362-32-7)

Peptide T is an HIV entry inhibitor that acts by blocking chemokine-5 receptors (CCR5), currently under clinical trials for the treatment of HIV-related neurolo...

Nevirapine
(CAS: 129618-40-2)

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS.

D77
(CAS: 497836-10-9)

D77 is anti-HIV-1 inhibitor, which inhibits HIV-1(IIIB) replication (EC50=23.8 μM)

NBD-557
(CAS: 333352-59-3)

NBD-557 is a N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analog, a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors th...

YYA-021
(CAS: 144217-65-2)

YYA-021 enhances the neutralization sensitivity of simian-human immunodeficiency virus (SHIV) carrying the envelope from the clade B clinical human immunodefici...

Ritonavir
(CAS: 155213-67-5)

Ritonavir is a very potent inhibitor of CYP3A4 mediated testosterone 6β-hydroxylation with mean Ki of 19 nM and also inhibits tolbutamide hydroxylation with IC5...

Saquinavir Mesylate
(CAS: 149845-06-7)

Saquinavir is an HIV Protease Inhibitor used in antiretroviral therapy. It inhibits both HIV-1 and HIV-2 proteases. Studies have also looked at saquinavir as a ...

Abacavir
(CAS: 136470-78-5)

Abacavir sulfate is a Nucleoside analog reverse transcriptase inhibitor (NRTI); guanosine analog used to treat HIV and AIDS.

BI 224436
(CAS: 1155419-89-8)

BI 224436 is a novel HIV-1 non-catalytic-site integrase inhibitor; has antiviral EC50s of <15 nM against different HIV-1 laboratory strains and cellular cytotox...

TAK-779
(CAS: 229005-80-5)

TAK-779 is a potent, dual antagonist at chemokine receptors CCR2 and CCR5 with IC50 = 1.4 nM at CCR5 and 2.3 nM at CCR2. Antagonists of both CCR2 and CCR5 such ...

Gomisin G
(CAS: 62956-48-3)

Gomisin G, carboxylic acid with additional oxygen functions, exhibited the most potent anti-HIV activity with EC50 and therapeutic index (TI) values of 0.006 mi...

BMS-707035
(CAS: 729607-74-3)

BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM.

CAS 544467-07-4 HIV-1 integrase inhibitor

HIV-1 integrase inhibitor
(CAS: 544467-07-4)

HIV-1 integrase inhibitor is uesful for anti-HIV, which can target HIV-1 integrase and depress the activity in the treatment of HIV infection, AIDS, and other s...

Darunavir
(CAS: 206361-99-1)

Darunavir is a second generation protease inhibitor that targets the HIV-1 protease. It demonstrates extremely potent activity against the infectivity and repli...

Nelfinavir
(CAS: 159989-64-7)

Nelfinavir is a HIV protease inhibitor; antiretroviral; and anti-tumor agent.

Zalcitabine
(CAS: 7481-89-2)

Zalcitabine is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI).

CAS 1051375-16-6 Dolutegravir (GSK1349572)

Dolutegravir (GSK1349572)
(CAS: 1051375-16-6)

Dolutegravir (GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM, modest activity against raltegravir-resistant signature mutants Y1...

CGP 57813
(CAS: 150608-41-6)

CGP 57813 has been found to be a HIV-1 protease inhibitor that has been once developed by Novartis.

Bevirimat
(CAS: 174022-42-5)

Bevirimat, also known as MPC-4326 and PA-457, is an anti-HIV drug derived from a betulinic acid-like compound, first isolated from Syzygium claviflorum, a Chine...

Lopinavir
(CAS: 192725-17-0)

Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM.

Chemical Structure

Quick Inquiry

Name:

* Email:

* Service & Products of Interest:

* Quantity:

Referral Code:

* Verification code:

Related HIV Products

Quick Inquiry

Featured Items

Drug Discovery

Chemistry

Life Science